Generic Entry Radar
Your BD team shouldn't be spending hours on manual Orange Book lookups for basic LOE screening. Generic Entry Radar surfaces near-term patent-cliff windows — scored, ranked, and ready for your first-pass review.
Built for early screening, not legal conclusions. Use it to prioritize which drugs deserve deeper IP and commercial diligence before engaging patent counsel.
LOE windows
Near-term Orange Book patent expiry signals, 12–48 months out.
Pharma BD & strategy
First-pass screening before IP counsel engagement or deal review.
Under 20 minutes
Sort by months to LOE, filter to your therapeutic area, open drug pages.
A typical Monday morning screen
- Open the watchlist sorted by months to LOE. Two drugs flag inside the 18–24 month window with patent complexity ≤ 1 and no clinical competition.
- Review each drug page. Therapeutic area, patent type breakdown (substance vs. use-code vs. product), market size tier, and a plain-English BD read — all in one place.
- Hand the shortlist to IP counsel. 20 minutes of screening, not a half-day of manual Orange Book lookups.
Which approved drugs may become commercially interesting as exclusivity changes?
Generic Entry Radar identifies U.S. small-molecule drugs approaching potential loss-of-exclusivity windows and enriches them with clinical-trial competition and patent-complexity signals — so teams can prioritize which names deserve deeper IP and commercial review.
Target users
- Generic pharma teams building a first-pass LOE opportunity queue
- Specialty pharma teams evaluating near-exclusivity-loss candidates
- Pharma competitive-intelligence teams monitoring the landscape
- BD and strategy teams screening small-molecule in-licensing opportunities
- Investors evaluating pharma patent-cliff positions
- Patent and regulatory strategy groups prioritizing review targets
Signals in one view
- Months to LOE and Orange Book patent expiry date
- Patent type breakdown — substance, product, or use-code
- Patent-thicket complexity score (1–5)
- Clinical competition score based on linked ClinicalTrials.gov activity
- Therapeutic area, indication, and estimated market size tier
What you can review today
20
Scored drug candidates in the public watchlist.
Data sourced from FDA Orange Book and ClinicalTrials.gov. Receive updated watchlist emails on request.
How teams use this module
- Build a watchlist of drugs with patent expirations in the next 18–36 months
- Identify products with simple versus complex patent landscapes before IP counsel engagement
- Monitor Orange Book updates and detect new late-expiring product or use-code patents
- Compare clinical competition around nearing-LOE products by therapeutic area
- Generate custom generic-entry opportunity reports for a specific drug class or indication
Receive Updated Watchlist by Email
The public list covers top candidates. Join the shared Treelip waitlist to receive updated Generic Entry Radar watchlists by email and choose future CSV deliveries.